Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aanika Balaji

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
JMIR Medical Education|February 22, 2022
Authors' Reply to: Techniques to Teach Students Effectively Using Telemedicine. Comment on "Incorporating Medical Students Into Primary Care Telehealth Visits: Tutorial"Aanika Balaji, Sarah Lou Clever
JMIR Medical Education|May 11, 2021
Incorporating Medical Students Into Primary Care Telehealth Visits: TutorialAanika Balaji, Sarah Lou Clever
Oncology (Williston Park, N.Y.)|October 31, 2017
Pneumonitis From Anti-PD-1/ PD-L1 TherapyAanika Balaji, Franco Verde, Karthik Suresh, et al.
Idcases|December 1, 2025
Late secondary syphilis mimicking anal carcinoma: A case illustrationAanika Balaji Warner, John Woller, Philip Wagner
BMJ Case Reports|July 26, 2022
Insulinoma mimic: methadone-induced hypoglycaemiaSarah Kanbour, Aanika Balaji, Kacey Chae, et al.
Immunotargets and Therapy|September 19, 2025
Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint InhibitorsMelissa Abel, Aanika Balaji Warner, Fatima Karzai, et al.
Clinical Lung Cancer|July 7, 2023
Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint InhibitorsMatthew Z Guo, Aanika Balaji, Joseph C Murray, et al.
Journal for Immunotherapy of Cancer|January 8, 2021
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomesAanika Balaji, Melinda Hsu, Cheng Ting Lin, et al.
Journal of Oncology Practice|August 7, 2019
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and OutcomesAanika Balaji, Jiajia Zhang, Beatriz Wills, et al.
Nature Communications|March 17, 2026
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept studyJunya Tabata, Tzu-Ting Huang, Elena Giudice, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
JMIR Medical Education|February 22, 2022
Authors' Reply to: Techniques to Teach Students Effectively Using Telemedicine. Comment on "Incorporating Medical Students Into Primary Care Telehealth Visits: Tutorial"Aanika Balaji, Sarah Lou Clever
JMIR Medical Education|May 11, 2021
Incorporating Medical Students Into Primary Care Telehealth Visits: TutorialAanika Balaji, Sarah Lou Clever
Oncology (Williston Park, N.Y.)|October 31, 2017
Pneumonitis From Anti-PD-1/ PD-L1 TherapyAanika Balaji, Franco Verde, Karthik Suresh, et al.
Idcases|December 1, 2025
Late secondary syphilis mimicking anal carcinoma: A case illustrationAanika Balaji Warner, John Woller, Philip Wagner
BMJ Case Reports|July 26, 2022
Insulinoma mimic: methadone-induced hypoglycaemiaSarah Kanbour, Aanika Balaji, Kacey Chae, et al.
Immunotargets and Therapy|September 19, 2025
Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint InhibitorsMelissa Abel, Aanika Balaji Warner, Fatima Karzai, et al.
Clinical Lung Cancer|July 7, 2023
Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint InhibitorsMatthew Z Guo, Aanika Balaji, Joseph C Murray, et al.
Journal for Immunotherapy of Cancer|January 8, 2021
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomesAanika Balaji, Melinda Hsu, Cheng Ting Lin, et al.
Journal of Oncology Practice|August 7, 2019
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and OutcomesAanika Balaji, Jiajia Zhang, Beatriz Wills, et al.
Nature Communications|March 17, 2026
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept studyJunya Tabata, Tzu-Ting Huang, Elena Giudice, et al.
Pageof 2